Home  |  Top News  |  Most Popular  |  Video  |  Multimedia  |  News Feeds  |  Feedback
  Medicine  |  Nature & Earth  |  Biology  |  Technology & Engineering  |  Space & Planetary  |  Psychology  |  Physics & Chemistry  |  Economics  |  Archaeology
Top > Medicine, Health Care > New Research Uncovers Diverse Metabolic… >
New Research Uncovers Diverse Metabolic Roles for PML Tumor Suppressor Gene

Published: August 30, 2012.
By Beth Israel Deaconess Medical Center
http://www.bidmc.harvard.edu

BOSTON -- Two papers led by scientific teams from the Cancer Genetics Program at Beth Israel Deaconess Medical Center (BIDMC) shed new light on the genetic mechanisms underlying cellular energy and metabolism and, at the same time, highlight both the challenges and opportunities of genetic approaches to cancer treatment.

Appearing in the September 2012 issues of The Journal of Clinical Investigation (JCI) and Nature Medicine, the new findings reveal surprising insights into how PML regulates metabolism via the fatty acid oxidation (FAO) pathway and, in the process, uncover paradoxical roles for this tumor suppressor gene.

"The real story lies in the juxtaposition of these two papers, the way they jointly illuminate the braided function of PML in the FAO pathway," says the papers' senior author Pier Paolo Pandolfi, MD, PhD, Director of Cancer Genetics at BIDMC and George C. Reisman Professor of Medicine at Harvard Medical School. The Pandolfi laboratory has been studying the PML (promyelocytic leukemia protein) tumor suppressor gene, for more than 20 years.

Fatty-acid oxidation is the fat-burning metabolic process that is of importance to the energy of all cells. The two studies examined the impact of the FAO process in different biomedical situations including obesity, breast cancer and hematopoetic stem cell maintenance. Importantly, both publications determined that the FAO pathway could be a target for pharmacologic treatments.

The JCI paper defines the mechanism by which PML regulates FAO (involving the regulation of peroxisome proliferator-activated receptors or PPARs). According to first author Arkaitz Carracedo, PhD, a former postdoctoral fellow in the Pandolfi laboratory and currently Ikerbasque Research Professor at the research institute CIC bioGUNE, Bizkaia, Spain, the findings demonstrate that alterations in this pathway result in excessive fat accumulation and obesity in genetically engineered mouse models. In other words, when PML is highly expressed, cellular metabolism is enhanced and the mice were able to briskly burn fat and avoid gaining weight. Conversely, when PML was lost, the animals grew obese.

But, the team also made the paradoxical discovery that PML's enhanced cellular metabolism appeared to provide breast cancer cells with the energy needed to survive. These findings are further supported by data showing PML is highly expressed in a subset of breast cancers with poor prognosis, notes Carracedo. Instead of maintaining its function as a tumor suppressor and keeping breast cancer cells under control, PML is providing breast cancer with a survival advantage. These findings aligned with work by other labs that have found a relationship between high PML expression and breast cancers with poor prognosis.

In the second paper, in the September 2012 issue of Nature Medicine, Keisuke Ito, MD PhD, together with co-lead author Arkaitz Carracedo, looked at PML's role in regulating hematopoetic stem cells (HSCs), again through the FAO pathway, and defined for the first time the contribution of lipid metabolism to maintaining the function of HSCs.

HSCs replenish blood cells throughout the lifespan of an organism, and so they are critical to the aging process, explains Ito, also a former postdoctoral fellow in the Pandolfi laboratory and currently a member of the faculty at the Albert Einstein College of Medicine. The authors discovered that inhibition of fatty acid oxidation could represent an effective therapy for leukemia, as well as other forms of cancer – but that it simultaneously posed a risk to the replenishment of HSCs. "Our results uncover a crucial metabolic requirement involving PPAR-delta signaling and FAO for preservation of the delicate equilibrium between HSC maintenance and function," the authors write. The findings have straightforward therapeutic implications for the improvement of both the efficacy of bone marrow transplantation (BMT) and the treatment of hematological malignancies.

"These two studies highlight both the opportunities and complexities of genetic approaches to human disease," notes Pandolfi. "Our next logical step will be to identify a potential path for therapeutic intervention through the opposing Scylla and Charybdis-like threats and benefits of this pathway," he says, referring to the two sea monsters that sailors of mythology had to navigate. "Through pharmacological dosage and scheduling, we will come up with a way to reap the benefits of PML and FAO regulation, while reducing or even eliminating its risks. The opportunity is there since we have drugs that can modulate both PML levels and FAO, and we have begun testing these concepts right away in our 'mouse hospital.'"




Show Reference »


Translate this page: Chinese French German Italian Japanese Korean Portuguese Russian Spanish


 
All comments are reviewed before being posted. We cannot accept messages that refer a product, or web site.If you are looking for a response to a question please use our another feedback page.
Related »

Tumor 
2/26/13 
Novel Combination Therapy Shuts Down Escape Route, Killing Glioblastoma Tumor Cells
By Ludwig Institute for Cancer Research
February 26, 2013, New York, N.Y. and San Diego, Calif. – Glioblastoma, the most common and lethal form of brain tumor in adults, is challenging to treat because the …
Signaling 
6/24/13 
New Understanding of Why Anti-cancer Therapy Stops Working at a Specific Stage
By The Hebrew University of Jerusalem
Jerusalem, June 23, 2013 –Researchers at the Hebrew University of Jerusalem and in California have achieved a breakthrough in understanding how and why a promising anti-cancer therapy has failed …
Cells 
7/28/10 
Tips from the American Journal of Pathology
By American Journal of Pathology
Transforming Growth Factor-βa (TGF-β1) Contributes to Kidney Disease …
Micrornas 
7/20/13 
Study Finds Missing Piece of Pediatric Cancer Puzzle
By Nationwide Children's Hospital
Most of the time, it takes decades of accumulating genetic errors for a tumor to develop. While this explains the general occurrence of cancer in adults, it leaves a …
Rapamycin 
10/3/12 
Penn-developed Mouse Model of Debilitating Lung Disease Suggests Potential Treatment Regimen
By University of Pennsylvania School of Medicine
PHILADELPHIA – LAM, short for pulmonary lymphangioleiomyomatosis, affects about 1 in 10,000 women of childbearing age and is characterized by proliferation of smooth muscle-like cells in the lung, destruction …
Cells 
11/19/12 
Fruit Fly Studies Guide Investigators to Misregulated Mechanism in Human Cancers
By Stowers Institute for Medical Research
KANSAS CITY, MO—Changes in how DNA interacts with histones—the proteins that package DNA—regulate many fundamental cell activities from stem cells maturing into a specific body cell type or blood …
Lacking 
4/30/14 
DNA Repair Gene Provides New Ideas for Disease Treatment
By Landes Bioscience
A gene known to repair DNA damage in healthy cells may also provide new insights about treating a genetic disorder of the bone marrow, Caltech researchers say. This …
More » 
 
© Newsline Group  |  About  |  Privacy Policy  |  Feedback  |  Mobile  |  Japanese Edition